HEALTH · L1

scheduled

health-02-64380f02 · seed health-02 · LinkedIn: TEXT_ONLY · Instagram: CAROUSEL

Instagram 1080×1350 · CAROUSEL · 5 frames

LinkedIn text only

Text-only post. No card ships on LinkedIn.

Facebook 1080×1080 · CAROUSEL · 5 frames

Status history

Generated · batch 64380f02Aug 18, 8:22 AM
ApprovedAug 18, 8:28 AM
Scheduled (drip) · scheduled for Thu 27 Aug · 10:30 ET (16:30 your time)Aug 18, 8:37 AM

LinkedIn caption

A funded lab tenant doesn't buy square footage.

They buy the date their team walks through the door and starts burning through grant money.

Every week the space sits unoccupied, that clock is running against them. Against their IRB approvals. Against their grant milestones. Against the window where their science actually matters.

And here is what most healthcare and life science developers get wrong: they treat speed-to-occupancy as a construction metric.

It is not a construction metric. It is a revenue and retention metric.

Your GC is optimizing the punch list.
Your funded tenant is watching their burn rate.

Those are not the same problem.

The invisible mistake: scope freezes late, submittals queue up, AHJ inspections get calendared instead of chased, and the tenant's move-in date slips six weeks. Nobody sends a change order for that. The cost just lands quietly inside the tenant's pro forma and inside your next lease negotiation.

Infection control sequencing, lab-specific AHJ signoffs, HVAC commissioning for BSL environments. Every one of those is a schedule constraint most GCs discover instead of plan for.

Speed-to-occupancy is not a delivery promise. It is the single variable your tenant used to decide whether to sign the next lease.

So here is the real question: if a funded lab tenant's move-in date slips by 30 days, who actually owns that cost, the developer, the GC, or the tenant, and does your contract reflect that clearly?

#HealthcareConstruction #LifeScience #LabTenants

Facebook captionInstagram caption

Regenerate

status: scheduled